AP82 Stock Chart & Stats
€65970.00
€0.00(0.00%)
At close: 4:00 PM EDT
€65970.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€65,970.00 - €65,970.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.73M
Enterprise Value-€0.28
Total Cash (Recent Filing)€9.80M
Total Debt (Recent Filing)€4.21M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Nov 05, 2026EPS Estimate
-3.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-211.18
Shares Outstanding1,801,970
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.00Price Target Upside-99.97% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-16.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform And IP ExpansionThe reusable dual-targeting backbone could support several therapeutic formats, including radiopharmaceuticals and T-cell engagers. Patent protection and platform reuse may broaden pipeline optionality and create more potential partnering opportunities.
Non-Dilutive Development FundingGrant funding helps finance APVO451 development without immediate equity issuance, while retaining project-related intellectual property. Milestone-backed support also provides external validation and extends resources for advancing the solid-tumor program.
Strategic Pipeline DiversificationThe collaboration combines Aptevo’s multispecific antibodies with Niowave’s radioisotopes, expanding the company into targeted alpha therapies. Shared development, isotope access, and partner equity alignment may improve pipeline breadth and execution capacity.
Bears Say
No Commercial RevenueThe absence of commercial revenue means operations are not yet self-funded and remain dependent on capital raising, grants, collaborations, or future licensing proceeds. This limits financial visibility and leaves value tied primarily to clinical and regulatory progress.
Persistent Cash BurnSustained operating and free-cash-flow deficits indicate that research spending continues to consume substantial cash without offsetting inflows. Unless programs generate partners or approvals, Aptevo will likely require ongoing external funding to maintain development.
Financing And Dilution RiskThe financing strengthens near-term liquidity but increases potential dilution through newly issued securities and warrants. Combined with recurring losses and fragile capital stability, repeated equity financing could constrain per-share value and strategic flexibility.
Aptevo Therapeutics News
AP82 FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was €65970.00 and its highest was €65970.00 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is €3.73M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on Aug 14, 2026. The company reported -€4.553 earnings per share for the quarter, beating the consensus estimate of -€5.157 by €0.604.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Overvalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate is -3.19.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,801,970 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -€4.553 in its last earnings report, beating expectations of -€5.157. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:AP82
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
AP82 Stock 12 Month Forecast
Average Price Target
€18.00
▼(-99.97% Downside)